JPH0823941A - Healthy beverage - Google Patents

Healthy beverage

Info

Publication number
JPH0823941A
JPH0823941A JP6160862A JP16086294A JPH0823941A JP H0823941 A JPH0823941 A JP H0823941A JP 6160862 A JP6160862 A JP 6160862A JP 16086294 A JP16086294 A JP 16086294A JP H0823941 A JPH0823941 A JP H0823941A
Authority
JP
Japan
Prior art keywords
diglyceride
exercise
acid
triglyceride
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6160862A
Other languages
Japanese (ja)
Other versions
JP3135791B2 (en
Inventor
Koji Kizawa
孝司 鬼沢
Hiroyuki Watanabe
浩幸 渡邉
Hiroe Honda
啓恵 本多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP06160862A priority Critical patent/JP3135791B2/en
Publication of JPH0823941A publication Critical patent/JPH0823941A/en
Application granted granted Critical
Publication of JP3135791B2 publication Critical patent/JP3135791B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

PURPOSE:To obtain a healthy beverage, containing a diglyceride and capable of utilizing and promoting the utilization of fats in the body during the motion. CONSTITUTION:This healthy beverage contains about >=0.01wt.%, preferably 1-10wt.% diglyceride. The diglyceride is a preferably a diester of a 6-22C (especially 14-22C) saturated or unsaturated fatty acid with glycerol. In the case of a mixture of the diglyceride with a monoglyceride or a triglyceride, >=50wt.% thereof in the whole glyceride is preferably the diglyceride.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は運動時に体内の脂肪をエ
ネルギー源として利用する作用を促進する健康飲料に関
する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a health drink that promotes the action of using fat in the body as an energy source during exercise.

【0002】[0002]

【従来の技術】従来より、数多くの健康飲料、特にスポ
ーツ時のエネルギー補給を目的とした飲料が開発されて
いる。例えば、エネルゲン(大塚製薬)などがあり、持
久運動時のエネルギー補給を目的としたものである。運
動に必要なエネルギーは、体内に貯蔵されている糖質と
脂肪から主に供給される。この2つのエネルギー源のう
ち糖質は短時間の急激な運動に利用され、脂肪は、持久
力的な運動に利用される。スポーツにおいては、体内に
保有する脂肪を有効的に使用し持久力を維持することが
大切である。
2. Description of the Related Art Conventionally, many health drinks, especially drinks for the purpose of supplementing energy during sports, have been developed. For example, there is Energen (Otsuka Pharmaceutical Co., Ltd.) and the like, which is for the purpose of energy supply during endurance exercise. The energy required for exercise is mainly supplied by sugars and fats stored in the body. Of these two energy sources, sugar is used for a short period of rapid exercise, and fat is used for endurance exercise. In sports, it is important to effectively use the fat held in the body to maintain endurance.

【0003】ところでエネルギー源として重要な脂肪の
本体はトリグリセリドであり、摂取された又は体内に蓄
積されたトリグリセリドは脂肪酸に分解された後、アセ
チルCoAを経てクエン酸回路によって代謝される。こ
の脂肪酸代謝と脂肪摂取とのバランスが良好であれば、
脂肪が過剰に体内に蓄積したり、また運動時のエネルギ
ーが不足したりすることがないと考えられる。
By the way, the main body of fat, which is important as an energy source, is triglyceride, and the triglyceride ingested or accumulated in the body is decomposed into fatty acid, and then metabolized by the citric acid cycle via acetyl CoA. If the balance between this fatty acid metabolism and fat intake is good,
It is considered that there is no excessive accumulation of fat in the body and lack of energy during exercise.

【0004】一方、ケトン体は、アセト酢酸、β−ヒド
ロキシ酪酸、アセトンの総称である。これら一群の化合
物は、主として肝臓で脂肪酸のβ酸化によってアセチル
CoAを生成するが、脂肪酸からのアセチルCoAが過
剰量になった時や、絶食、糖尿病などで生体内の糖の利
用性が低下した時に増加する。特に病態時でない場合で
も、糖代謝においてTCAサイクルが低下した場合にも
ケトン体が増加することが知られている。生成したケト
ン体は、エネルギーの必要時には心臓や骨格筋におい
て、エネルギー源としても利用される。従って、エネル
ギーの必要時に血中ケトン体を増加させる作用を有する
物質は、体内に蓄積している脂肪の利用を促進させ、健
康飲料の成分として有用であると考えられる。
On the other hand, the ketone body is a general term for acetoacetic acid, β-hydroxybutyric acid and acetone. These groups of compounds produce acetyl-CoA mainly by β-oxidation of fatty acids in the liver, but when the amount of acetyl-CoA from fatty acids becomes excessive, fasting, diabetic, etc., the availability of sugar in the body is reduced. Sometimes increases. It is known that the number of ketone bodies increases even when the TCA cycle is decreased in glucose metabolism, even when the condition is not pathological. The generated ketone bodies are also used as an energy source in the heart and skeletal muscle when energy is needed. Therefore, it is considered that a substance having an action of increasing blood ketone bodies when energy is needed promotes utilization of fat accumulated in the body and is useful as a component of a health drink.

【0005】[0005]

【発明が解決しようとする課題】従って、本発明の目的
はエネルギーの必要時に体内の脂肪の利用を促進する健
康飲料を提供することにある。
SUMMARY OF THE INVENTION It is therefore an object of the present invention to provide a health drink that promotes the use of fat in the body when energy is needed.

【0006】[0006]

【課題を解決するための手段】そこで本発明者らは脂肪
の摂取と尿中ケトン体排泄量との関係について種々検討
した結果、意外にもジグリセリドがトリグリセリドに比
べてエネルギーの必要な運動時に体内に蓄積している脂
肪の利用を促進する作用を有することを見出し、本発明
を完成するに至った。
Therefore, as a result of various studies on the relationship between the intake of fat and the excretion of ketone bodies in the urine, the present inventors have surprisingly found that diglycerides are more active in the body during exercise, which requires more energy than triglycerides. It has been found that it has an action of promoting the use of fat accumulated in the above, and has completed the present invention.

【0007】すなわち、本発明は、ジグリセリドを含有
する健康飲料を提供するものである。
That is, the present invention provides a health drink containing diglyceride.

【0008】本発明に用いられるジグリセリド、すなわ
ち、脂肪酸のグリセリンジエステルは、炭素原子数6〜
22(特に、炭素原子数14〜22)の飽和若しくは不
飽和の脂肪酸とグリセリンとのジエステルであることが
好ましい。炭素原子数6〜22の飽和脂肪酸の例として
は、ラウリン酸、ミリスチン酸、パルミチン酸、ステア
リン酸、アラキン酸、そしてベヘン酸を挙げることがで
きる。炭素原子数6〜22の不飽和脂肪酸の例として
は、パルミトオレイン酸、オレイン酸、エライジン酸、
イソオレイン酸、ペトロセリン酸、エルカ酸、リノール
酸、そしてリノレイン酸を挙げることができる。
The diglyceride used in the present invention, that is, glycerin diester of fatty acid, has 6 to 6 carbon atoms.
It is preferably a diester of a saturated or unsaturated fatty acid having 22 (particularly, 14 to 22 carbon atoms) and glycerin. Examples of saturated fatty acids having 6 to 22 carbon atoms include lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, and behenic acid. Examples of unsaturated fatty acids having 6 to 22 carbon atoms include palmitooleic acid, oleic acid, elaidic acid,
Mention may be made of isooleic acid, petroselinic acid, erucic acid, linoleic acid and linoleic acid.

【0009】本発明に用いるジグリセリドは、不飽和脂
肪酸成分の多い脂肪酸組成を持つことが望ましい。すな
わち、本発明でジグリセリドは、不飽和脂肪酸基が全脂
肪酸基の70重量%以上を占めることが望ましく、特に
80重量%以上であることが望ましい。そして、ジグリ
セリドの大部分がジ不飽和脂肪酸グリセリドであること
が望ましい。なお、本発明においてジグリセリドは、単
独で用いても良いが、ジグリセリドのみを単離すること
は工業上で容易でないため、モノグリセリドあるいはト
リグリセリドとの混合物として用いてもよい。ただし、
その場合には全グリセリド中の50重量%以上がジグリ
セリドであることが望ましい。
The diglyceride used in the present invention preferably has a fatty acid composition containing a large amount of unsaturated fatty acid components. That is, in the diglyceride of the present invention, the unsaturated fatty acid groups preferably account for 70% by weight or more of the total fatty acid groups, and particularly preferably 80% by weight or more. And it is desirable that most of the diglycerides are diunsaturated fatty acid glycerides. In the present invention, the diglyceride may be used alone, but since it is not industrially easy to isolate the diglyceride, it may be used as a mixture with a monoglyceride or a triglyceride. However,
In that case, it is desirable that 50% by weight or more of all glycerides is diglycerides.

【0010】本発明において好ましく用いられるジグリ
セリドは、たとえば、不飽和脂肪酸基の含有量が多い油
脂(例、サフラワー油、オリーブ油、綿実油、コーン
油、菜種油、大豆油、パーム油、ひまわり油、ごま油;
ラード、牛脂、魚油、乳脂、あるいはそれらの分別油、
ランダム化油、硬化油、エステル交換油)から選ばれた
一種あるいは二種以上の油脂とグリセリンとを、アルカ
リ金属又はアルカリ土類金属の水酸化物の存在下でエス
テル交換させるか、又はこれらの油脂由来の不飽和脂肪
酸含量の高い脂肪酸混合物とグリセリンとのエステル化
反応により得ることができる。反応で生成した過剰のモ
ノグリセリドは分子蒸留法又はクロマトグラフィーなど
の分離手段を利用して除去することができる。なお、こ
れらの反応は上記のようなアルカリ触媒等を用いた化学
反応によっても実施することができるが、1,3−位選
択的リパーゼ等の酵素を用いて温和な条件で反応を行う
方が、得られるジグリセリドの風味もよく、好ましい。
The diglyceride preferably used in the present invention includes, for example, fats and oils having a large content of unsaturated fatty acid groups (eg, safflower oil, olive oil, cottonseed oil, corn oil, rapeseed oil, soybean oil, palm oil, sunflower oil, sesame oil). ;
Lard, beef tallow, fish oil, milk fat, or fractionated oils thereof,
One or more kinds of fats and oils selected from randomized oils, hydrogenated oils, transesterified oils) and glycerin are transesterified in the presence of a hydroxide of an alkali metal or an alkaline earth metal, or It can be obtained by an esterification reaction of a fatty acid mixture having a high unsaturated fatty acid content derived from fats and oils and glycerin. The excess monoglyceride produced by the reaction can be removed by using a separation means such as a molecular distillation method or chromatography. Although these reactions can be carried out by a chemical reaction using an alkali catalyst as described above, it is better to carry out the reaction under mild conditions using an enzyme such as a 1,3-position selective lipase. The obtained diglyceride has a good flavor and is preferable.

【0011】本発明で用いられるジグリセリドは、天然
食用油脂の分別によっても得ることができる。
The diglyceride used in the present invention can also be obtained by fractionating natural edible oils and fats.

【0012】これらのジグリセリドのラットにおける経
口急性毒性は10g/kg体重以上であり、安全性の高い
ものである。
The oral acute toxicity of these diglycerides in rats is 10 g / kg body weight or more, which is highly safe.

【0013】本発明の健康飲料へのジグリセリドの配合
量は、特に制限されないが、0.01重量%以上が好ま
しく、0.01〜30重量%がより好ましく、1〜10
重量%が特に好ましい。
The blending amount of diglyceride in the health drink of the present invention is not particularly limited, but is preferably 0.01% by weight or more, more preferably 0.01 to 30% by weight, and 1 to 10%.
Weight percent is particularly preferred.

【0014】本発明の健康飲料には、ジグリセリド以外
に通常の清涼飲料水に配合できる成分、例えば砂糖、果
糖、ブドウ糖、液糖等の甘味料、食塩、塩化カリウム、
塩化マグネシウムなどのミネラル類、ビタミン類、クエ
ン酸、リンゴ酸、酒石酸などの有機酸、アミノ酸等を配
合することができるが、これに限定されるものではな
い。
In addition to diglycerides, the health drink of the present invention contains ingredients that can be added to ordinary soft drinks, for example, sweeteners such as sugar, fructose, glucose and liquid sugar, salt, potassium chloride,
Minerals such as magnesium chloride, vitamins, organic acids such as citric acid, malic acid, tartaric acid, amino acids and the like can be added, but the present invention is not limited thereto.

【0015】[0015]

【実施例】次に実施例を挙げて本発明を更に説明する
が、本発明はこれに限定されるものではない。
The present invention will be further described with reference to examples, but the present invention is not limited thereto.

【0016】以下の各実施例で用いたジグリセリドは、
下記の方法で製造したものである。固定化1,3−位選
択的リパーゼである市販リパーゼ製剤(ノボインダスト
リA.S社製、商品名:Lypozyme 3A)を触
媒として、表1の脂肪酸組成を有する菜種油由来脂肪酸
860gとグリセリン140gとを40℃で反応させ
た。反応後リパーゼ製剤を濾別したのち、反応生成物を
分子蒸留にかけ、常法により精製して、脂肪酸基の大部
分が不飽和脂肪酸である、ジグリセリド80重量%、ト
リグリセリド18重量%及びモノグリセリド2重量%か
らなるグリセリド混合物を得た。なお、以下に示すジグ
リセリドの使用量は、この混合物の使用量である。
The diglyceride used in each of the following examples is
It is manufactured by the following method. 860 g of rapeseed oil-derived fatty acid having a fatty acid composition of Table 1 and 140 g of glycerin, using a commercially available lipase preparation (Novo Industri AS Co., trade name: Lypozyme 3A) that is an immobilized 1,3-position selective lipase as a catalyst. Was reacted at 40 ° C. After the reaction, the lipase preparation is filtered off, and the reaction product is subjected to molecular distillation and purified by a conventional method to obtain 80% by weight of diglyceride, 18% by weight of triglyceride and 2% by weight of monoglyceride in which most of the fatty acid groups are unsaturated fatty acids. % Glyceride mixture was obtained. The amount of diglyceride used below is the amount of this mixture used.

【0017】[0017]

【表1】 [Table 1]

【0018】また、以下の各実施例で用いたトリグリセ
リドは、上記と同じ脂肪酸組成の菜種油である。
The triglyceride used in each of the following examples is a rapeseed oil having the same fatty acid composition as above.

【0019】実施例1 A.試験方法 (1)表2のスケジュールで、SD系雄性ラット11週
齢(180〜182g)に20%のジグリセリド及びト
リグリセリドを配合した食餌を1週間与え、血中及び、
尿中のケトン体を測定した。
Example 1 A. Test method (1) According to the schedule shown in Table 2, 11-week-old SD male rats (180 to 182 g) were fed with a diet containing 20% of diglyceride and triglyceride for 1 week, in the blood and
The ketone bodies in urine were measured.

【0020】[0020]

【表2】 [Table 2]

【0021】(2)また、高エネルギー利用状態のモデ
ルとして、運動を負荷した場合と運動のない通常のエネ
ルギー利用状態のモデルについても比較検討を行った。
なお、運動負荷は、表3のスケジュールでトレッドミル
(夏目製作所製)を用いて強制運動を負荷した。
(2) Further, as a model of a high energy utilization state, a comparative study was carried out with respect to a model in which exercise is applied and a model in a normal energy utilization state without exercise.
As for the exercise load, a forced exercise was applied using a treadmill (Natsume Seisakusho) according to the schedule shown in Table 3.

【0022】[0022]

【表3】 [Table 3]

【0023】食餌に用いた飼料組成は表4の通りであ
る。
The feed composition used in the diet is shown in Table 4.

【0024】[0024]

【表4】 [Table 4]

【0025】*1,*2:AIN86配合 *3 :トリグリセリドと脂肪酸量をあわせる為に2
1.0%とした。
* 1, * 2: AIN86 blended * 3: 2 to match the amount of triglyceride and fatty acid
It was 1.0%.

【0026】なお、血中及び尿中ケトン体濃度の測定は
臨床医vol.9,増刊号1811〜1814及びクリ
ニカ キミカ アクタ(Clinica Chimic
aAct),134;327−336に記載の方法に準
じて行った。
The blood and urine ketone body concentrations are measured by a clinician, vol. 9, special issue 1811-1814 and Clinica Chimica
aAct), 134; 327-336.

【0027】B.試験結果 結果を表5〜表8に示す。B. Test results The results are shown in Tables 5-8.

【0028】[0028]

【表5】 [Table 5]

【0029】表5より、運動負荷群は、非運動群に比較
して、体重、各臓器重量は低値を示したが、ジグリセリ
ド投与群とトリグリセリド投与群間では差は認められな
かった。
From Table 5, the exercise load group showed lower body weight and organ weights than the non-exercise group, but no difference was observed between the diglyceride administration group and the triglyceride administration group.

【0030】[0030]

【表6】 [Table 6]

【0031】表6より、運動負荷群は、非運動群に比較
して、摂食量は低値を示したが、ジグリセリド投与群と
トリグリセリド投与群間での差は認められなかった。
From Table 6, the amount of food intake in the exercise load group was lower than that in the non-exercise group, but no difference was observed between the diglyceride administration group and the triglyceride administration group.

【0032】[0032]

【表7】 [Table 7]

【0033】表7より、運動をすることにより血中ケト
ン体量は増加したが、ジグリセリド投与群とトリグリセ
リド投与群間での差は認められなかった。
From Table 7, the amount of ketone bodies in blood increased by exercising, but no difference was observed between the diglyceride administration group and the triglyceride administration group.

【0034】[0034]

【表8】 [Table 8]

【0035】表8より、血中ケトン体量は運動負荷群及
び非運動群においても各群間で差は認められなかった。
一方、尿中ケトン体量は運動負荷群では、ジグリセリド
投与群はトリグリセリド投与群に比較して有意に低値を
示した。また、非運動群では、ジグリセリド投与群はト
リグリセリド投与群に比較して有意に高値を示した。
From Table 8, no difference in the amount of ketone bodies in blood was observed between the exercise load group and the non-exercise group.
On the other hand, the amount of urinary ketone bodies in the exercise-loaded group was significantly lower in the diglyceride-administered group than in the triglyceride-administered group. In the non-exercise group, the diglyceride administration group showed a significantly higher value than the triglyceride administration group.

【0036】表5〜表8より、運動負荷しないラットに
おいては、血中のケトン体量には差は認められなかった
ものの、尿中へのケトン体排泄量は、ジグリセリド食で
高値を示した。このことは、ジグリセリドが食餌又は、
体脂肪由来の脂肪酸をケトン体に変え、尿中へ排泄し、
脂肪の体蓄積を抑制していることを示す。運動を負荷し
たラットにおいては、尿中のケトン体は、トリグリセリ
ド群に比較してジグリセリド群では低値を示した。一
方、血中ケトン体はジグリセリド食群及びトリグリセリ
ド食群とも、運動前に比較して運動後に上昇し、その値
は両食餌群で差は認められなかった。このことは、ジグ
リセリドが体内の脂肪を運動時のエネルギー源として利
用すると同時に、ジグリセリドから生成されるケトン体
をもエネルギー源として利用し、尿中へのケトン体排泄
が低下したものと考えられる。すなわち、運動時におい
てもジグリセリドは体内への脂肪酸を利用して体内への
蓄積を抑制している。
From Tables 5 to 8, there was no difference in the amount of ketone bodies in the blood of rats not subjected to exercise, but the amount of excreted ketone bodies in the urine was high on the diglyceride diet. . This means that diglyceride is dietary or
Converts fatty acids derived from body fat into ketone bodies, excreted in urine,
It shows that the body accumulation of fat is suppressed. In exercise-treated rats, urinary ketone bodies were lower in the diglyceride group than in the triglyceride group. On the other hand, blood ketone bodies increased after exercise in both the diglyceride diet group and the triglyceride diet group, and the values were not different between both diet groups. It is considered that this is because diglycerides use the fat in the body as an energy source during exercise, and at the same time, the ketone bodies produced from the diglycerides are also used as an energy source, and the excretion of ketone bodies in urine is reduced. That is, even during exercise, diglyceride utilizes fatty acids in the body to suppress accumulation in the body.

【0037】実施例2Example 2

【0038】[0038]

【表9】 健康飲料組成 クエン酸 50mg ビタミンB1 5mg ビタミンB2 5mg ビタミンB6 5mg ビタミンC 20mg カフェイン 50mg ブドウ糖 10g 果糖 3g 塩化ナトリウム 50mg 塩化カリウム 50mg アラニン 100mg ジグリセリド 5g ドリンクフレーバー 微量 ミネラルウォーター バランス[Table 9] Healthy drink composition Citric acid 50 mg Vitamin B 1 5 mg Vitamin B 2 5 mg Vitamin B 6 5 mg Vitamin C 20 mg Caffeine 50 mg Glucose 10 g Fructose 3 g Sodium chloride 50 mg Potassium chloride 50 mg Alanine 100 mg Diglyceride 5 g Drink flavor Minor mineral water balance

【0039】[0039]

【発明の効果】本発明の健康飲料を摂取すれば、スポー
ツ時等のエネルギー必要時に体内に蓄積した脂肪の利用
を促進し、積極的に必要なエネルギーを供給することが
できる。
EFFECTS OF THE INVENTION By ingesting the health drink of the present invention, it is possible to promote utilization of fat accumulated in the body when energy is needed during sports and to positively supply necessary energy.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 ジグリセリドを含有する健康飲料。1. A health drink containing diglyceride. 【請求項2】 全グリセリド中50重量%がジグリセリ
ドである油脂を含有する健康飲料。
2. A health drink containing fats and oils in which diglycerides account for 50% by weight of all glycerides.
【請求項3】 ジグリセリドの含有量が0.01重量%
以上である請求項1又は2記載の健康飲料。
3. The content of diglyceride is 0.01% by weight.
It is above, The healthy drink of Claim 1 or 2.
JP06160862A 1994-07-13 1994-07-13 Health drink Expired - Fee Related JP3135791B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP06160862A JP3135791B2 (en) 1994-07-13 1994-07-13 Health drink

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP06160862A JP3135791B2 (en) 1994-07-13 1994-07-13 Health drink

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2000232608A Division JP2001098294A (en) 2000-08-01 2000-08-01 Utilization promoter for internal depot fat

Publications (2)

Publication Number Publication Date
JPH0823941A true JPH0823941A (en) 1996-01-30
JP3135791B2 JP3135791B2 (en) 2001-02-19

Family

ID=15723991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP06160862A Expired - Fee Related JP3135791B2 (en) 1994-07-13 1994-07-13 Health drink

Country Status (1)

Country Link
JP (1) JP3135791B2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6478069B1 (en) 1999-02-03 2002-11-12 Origin Electric Company, Limited Manufacturing method and apparatus for optical disc
US6495045B2 (en) 2000-06-19 2002-12-17 Nippon Shokubai Co., Ltd. Solid substance removing device
US6749881B2 (en) 2001-03-26 2004-06-15 Kao Corporation Packaged emulsified beverage
EP1600063A1 (en) * 2004-02-24 2005-11-30 Kao Corporation Composition to improve the endurance
JP2006158379A (en) * 2004-11-15 2006-06-22 Kao Corp Packed drink for promoting burning of lipid
JP2007112806A (en) * 2006-11-27 2007-05-10 Kao Corp Agent for promoting body-fat burning
EP3488706A4 (en) * 2016-07-22 2020-03-25 Suntory Holdings Limited Caffeine-containing colorless transparent drink
CN116076725A (en) * 2023-04-07 2023-05-09 北京衡美金叶营养健康科技有限公司 Composition for promoting body metabolism and reducing fat as well as preparation method and application thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6478069B1 (en) 1999-02-03 2002-11-12 Origin Electric Company, Limited Manufacturing method and apparatus for optical disc
US6746564B2 (en) 1999-02-03 2004-06-08 Origin Electric Company, Limited Manufacturing method and apparatus for optical disc
US6495045B2 (en) 2000-06-19 2002-12-17 Nippon Shokubai Co., Ltd. Solid substance removing device
US6749881B2 (en) 2001-03-26 2004-06-15 Kao Corporation Packaged emulsified beverage
EP1600063A1 (en) * 2004-02-24 2005-11-30 Kao Corporation Composition to improve the endurance
JP2006158379A (en) * 2004-11-15 2006-06-22 Kao Corp Packed drink for promoting burning of lipid
JP2007112806A (en) * 2006-11-27 2007-05-10 Kao Corp Agent for promoting body-fat burning
EP3488706A4 (en) * 2016-07-22 2020-03-25 Suntory Holdings Limited Caffeine-containing colorless transparent drink
CN116076725A (en) * 2023-04-07 2023-05-09 北京衡美金叶营养健康科技有限公司 Composition for promoting body metabolism and reducing fat as well as preparation method and application thereof

Also Published As

Publication number Publication date
JP3135791B2 (en) 2001-02-19

Similar Documents

Publication Publication Date Title
EP1681945B1 (en) Human breast milk lipid mimetic as dietary supplement
US6248909B1 (en) Triglyceride and composition comprising the same
JP3021499B2 (en) Randomized palm oil composition for infant formula
KR100678831B1 (en) Phytosterol and/or phytostanol derivatives
US6608222B2 (en) Bioactive conjugated linoleic acid glycerides and method of use
EP2330916A2 (en) Sn-2 myristate-containing edible oil
EP2538794B1 (en) Balanced myristate- and laurate-containing edible oil
WO2002016534A1 (en) Fat compositions
US4952606A (en) Structured lipid containing dairy fat
CA2196880C (en) Nervonic acid compositions
JP3135791B2 (en) Health drink
JP2925085B2 (en) Dietary fats and oils and foods containing the same
JPH0826988A (en) Eliminant for ketone derivative into urine
JP2001098294A (en) Utilization promoter for internal depot fat
JPWO2003056928A1 (en) Oil composition for lowering blood lipid
GB2266217A (en) Processes for producing low calorie chocolate having cholesterol reducing effects in blood
EP3884783B1 (en) Oil and fat composition
AU2011348012B2 (en) Water-in-oil emulsion comprising omega-3 fatty acids and process for the manufacture thereof
JP3135370B2 (en) Low calorie fat
JP4772295B2 (en) Exercise capacity improver containing conjugated fatty acid as an active ingredient
AU711302C (en) Nervonic acid compositions
JP2024051305A (en) Carbohydrate burning promoter
KR100200331B1 (en) Feed compositions for rainbow trout
Wah Positional Fatty Acids in Triacylglycerols and Their Adiposity Behaviour in C57bl/6 Mice
Gouk Positional fatty acids in triacylglycerols and their adiposity behaviour in C57BL/6 mice/Gouk Shiou Wah

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071201

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081201

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081201

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091201

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091201

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101201

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101201

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111201

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111201

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121201

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121201

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131201

Year of fee payment: 13

LAPS Cancellation because of no payment of annual fees